BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, has received a contract from Irish biotechnology firm, Celtic Biotech Ltd., to provide GMP-certified drug production of CB-24 for Celtic Biotech’s upcoming European clinical trial. CB-24 is Celtic Biotech’s leading drug candidate for the treatment of cancer.
